Quantcast
Last updated on April 18, 2014 at 5:48 EDT

Latest Immunohistochemistry Stories

2014-04-11 16:21:38

DALLAS, April 11, 2014 /PRNewswire/ -- The "Tissue Diagnostics Market by Technology (Immunohistochemistry, in Situ Hybridization, Digital pathology & Workflow, Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non Small Cell Lung Cancer and Others), Product (Instruments and Consumables), End-Users (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research Organizations and Others) & by Region (The Americas,...

2014-04-03 12:28:49

TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF®-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the...

2014-03-11 08:31:51

TUCSON, March 11, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into a multi-year agreement with Bayer Pharma AG (Bayer) to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer's portfolio of targeted therapy projects. This new agreement extends an already existing collaboration and focuses on the development of diagnostic tests for Bayer's biomarker targeted...

2014-02-27 23:22:58

An article in the recent issue of Pediatric and Developmental Pathology analyzes 18 surgical resections from infants less than 14 months old using three techniques: hematoxylin and cosin staining, Hu C/D neural markers, and calretinin immunohistochemistry. Testing for calretinin-immunoreactive mucosal innervation has begun to replace other methods in laboratories because it requires a less specialized methodology, however VS-HD remains a challenge to diagnose. Lawrence, Kansas (PRWEB)...

2014-01-13 04:21:04

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Study supported by a EUR3.5 million IWT grant from the Flemish Government arGEN-X, a clinical stage human therapeutic antibody company, announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. The objective is to further investigate the safety of ARGX-110 in CD70-positive cancer patients with either...

2013-12-05 08:29:39

Companion Algorithm ER (SP1) image analysis software clearance completes the company's breast diagnostic portfolio, providing physicians with the industry's only FDA-cleared testing package of five key breast biomarkers with their corresponding image analysis algorithms and digital read applications for cancer patients TUCSON, Ariz., Dec. 5, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and...

2013-11-05 12:28:52

TUCSON, Ariz., Nov. 5, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program. As part of the agreement, Ventana will support Incyte's personalized medicine healthcare strategies for cancer drug development using its vast...

2013-10-28 23:01:00

Rockland Immunochemicals Inc. has received a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute, National Institutes of Health (NCI/NIH) to develop nanoprobes for in vivo imaging of cancer cells and tumors that express one of the three important cancer therapeutic targets: EGFR, Her2 and Mesothelin. This project is a joint collaboration between Rockland and Abzyme Therapeutics with in vivo imaging consultants from Yale University and the University...

2013-10-01 12:31:10

Exclusive license agreement paves the way for industry's first BRAF V600E IHC test TUCSON, Ariz., Oct 1, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the global launch of the industry's first BRAF V600E immunohistochemistry (IHC) test(1) to detect the BRAF V600E mutation in a variety of tumors. The test is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of...

2013-09-30 13:15:10

New results from a trial of an antibody that helps the immune system to recognize and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers. Presenting the most up-to-date data from 85 patients with non-small cell lung cancer in a large, phase I clinical trial of an experimental drug called MPDL3280A, Professor Jean-Charles Soria told the 2013 European Cancer Congress (ECC2013) today (Sunday): "This is the first study to suggest a...